ATCC® VIROLOGY GUIDE

Tips and techniques for propagating virus in

tissue culture and embryonated chicken eggs

THE ESSENTIALS OF
LIFE SCIENCE RESEARCH
GLOBALLY DELIVERED™
CoolCell
LX Container
®

We’ve taken cryopreservation

to the next level of “cool”
The CoolCell® LX container is the definitive
cryopreservation tool, providing:
• Ample sample space to create
working stocks
• Durable, alcohol-free construction
• Dependable freezing rate
An easy-to-use device designed to support
cell, viral, bacterial, protozoan, and fungal
cultures using a slow freezing rate of -1˚C
per minute in a standard -80˚C freezer.
Trust the leader in cryopreservation
techniques, with over 85 years of
experience, and order your CoolCell® LX
Container (ATCC® No. ACS-6000™) today!

www.atcc.org/CoolCell

CoolCell® is a registered trademark of BioCision, LLC.

ATCC® is a registered trademark of the American
Type Culture Collection.
 

Table of Contents
This guide contains general technical information for viral growth, propagation, preservation, and
application. Additional information on viral culturing can be requested from ATCC Technical Services at
[email protected] or can be found in A Manual of Basic Virological Techniques¹.

Getting Started with an ATCC Viral Strain....1 Biosafety and Disposal..................................21

Product Sheet..............................................................1 Biosafety..................................................................... 21
Viral Taxonomy ...........................................................1 Disposal of Infectious Materials......................... 21
Viral Replication..........................................................1
Preparation of Propagation Host and Viral Authentication and Viability Testing.22
Reagents........................................................................2 Viability Testing........................................................ 22
Opening Glass Ampoules Containing Frozen Viral Authentication............................................... 23
Material..........................................................................2
Initiating Frozen Cultures........................................2 Viral Applications...........................................24
Initiating Lyophilized Cultures..............................3 Cell Transformation................................................ 24
Phage Therapy.......................................................... 24
Viral Replication and Propagation................4 Nanotechnology...................................................... 24
Propagation Host Range.........................................4 Recombinant Vectored Vaccines....................... 25
Viral Propagation........................................................5
Propagation of Common Viruses and Glossary............................................................26
Chlamydia........................................................... 7
Viral Titering.................................................................9 Appendix..........................................................27

Growth Media for Tissue Culture-Adapted References.......................................................28

Viruses 12 ATCC Reagents for Virus Expansion ...........31
Media for Culturing Propagation Hosts.......... 12
Media Formulations............................................... 13
Media Supplements............................................... 13

Preservation....................................................15
Cryopreservation..................................................... 15
Lyophilization........................................................... 18
Preservation of Specific Strains.......................... 20
Special Hazards........................................................ 20

Phone 800.638.6597 www.atcc.org

Getting Started with an ATCC Viral Strain
Getting Started with an ATCC Viral Strain
ATCC viral strains are predominantly shipped either frozen on dry ice in plastic cryopreservation vials, or as
lyophilized materials within glass ampoules or serum vials. Upon receipt of frozen material, either thaw and
transfer the viral agent to an appropriate propagation host, or briefly store the frozen material between
-70°C and -80°C to allow time to seed host cells. However, please note that the viability of some materials
may decline at temperatures above -120°C. Upon receipt of freeze-dried strains, reconstitute cultures with
sterile, double-distilled water and add the rehydrated material to an appropriate propagation host. If this is
not possible, store the vials in liquid nitrogen vapor phase (below -120°C).

Product Sheet
ATCC viral strains are shipped with a product sheet that contains information on the production host and
recommendations for infection. The product sheet and additional information can be found on the ATCC
website or can be requested from the ATCC Technical Service Department.

Viral Taxonomy
Viruses are placed into taxonomic groups based on characteristics including morphology, genome type,
and host organism. Viral agents can significantly vary in size, often
ranging between 20 and 300 nanometers in diameter. They also vary
in structure, including helical, icosahedral, prolate, enveloped,
and complex morphologies.
In addition to unique morphological structures, viruses also vary in
genomic structure. Unlike other microorganisms that have double
stranded DNA as genomic material, viral genomes can be composed
of double-stranded DNA, single-stranded DNA, double-stranded
RNA, or single-stranded RNA. Single-stranded RNA viruses can be
further described as positive sense, negative sense, or ambisense. Influenza ultra-structure courtesy of Jordan
For more detailed information on the various morphological and Douglas, CDC
genomic types, please refer to the glossary.
Changes in taxonomy or further analysis of viral strains may lead to a change in nomenclature. Taxonomic
nomenclature as well as the common name can be found on the product sheet. Further information on viral
nomenclature is available online at http://ictvonline.org/.

Viral Replication
Viruses are pathogenic intracellular organisms requiring living cells in order to multiply. The virus life-
cycle can be divided into three major steps: attachment, assembly, and release. Generally, infection is
established when the virus binds to a specific cellular receptor and enters the host cell. Upon cellular entry,
host proteins are recruited to assist with viral replication. Once viral structural proteins are generated, new
viruses assemble within the cell. Depending on the nature of the viral agent, the replication and assembly
process can vary in cellular location and process. Following viral assembly, new infectious particles either
remain cell-associated or exit the cell via lysis or virus shedding.

page 1 www.atcc.org Email [email protected]

 Getting Started with an ATCC Viral Strain
Preparation of Propagation Host and Reagents
In advance, prepare the propagation host and associated reagents necessary for viral propagation.
Information for the preparation of these products is available on the provided product sheet.

Opening Glass Ampoules Containing FREEZE-DRIED PREPARATIONS

Frozen Material
Tip
Insulator
Overview Cotton plug
All cultures should be considered
Outer potentially hazardous
vial (soft glass) Borosilicate glass
Inner vial
and should be opened Freeze-driedby individuals trained in
pellet Freeze-dried virus
microbiological techniques. Cotton Work should only be
Desiccant with indicator
carried out in facilities with containment requirements
appropriate for the biosafety level of the cultures. The
handling or opening of glass ampoules containing These preparations may be enclosed in a thin skin of
virusHeat
material must
the tip of be performed in a biological safety
the outer cellulose; this skin must be removed (either with a sharp
vial in a flame blade or by soaking in water for a few minutes). Score the
cabinet. Ensure that all empty vials are sterilized before ampule once briskly with a sharp file about one inch
disposal. from the tip.

1. Disinfect the outside of the ampoule with freshly

prepared 70% ethanol or dip it into a beaker of
freshly prepared 70% ethanol.
2. To recover the material from the glass ampoule,
score
Squirt athe neckofofwater
few drops the ampoule with a sterile, small
on the hot tip to crack glass
file.
3. Wrap the ampoule within several folds of a sterile
towel or gauze to dry residual ethanol. Disinfect the ampule with alcohol-dampened gauze

4. Working in a biological safety cabinet, hold the vial

upright and snap open the vial. Ensure that your
gauze does not become too wet with ethanol, or
ethanol could be sucked into the culture when the
Strike withis
vacuum filebroken.
or Propagate the virus immediately.
pencil to remove tip

Initiating Frozen Cultures

Tissue Culture-Adapted Strains Wrap gauze around the ampule, and break at the scored area.
Care should be taken not to have the gauze too wet, or
1. In advance, prepare the cell growth medium for alcohol could be sucked into the culture when the vacuum is
growing the host cell line. Additionally, prepare broken. Rehydrate material at once.

the virus
Remove growth
insulation andmedium for virus propagation as
inner vial with
forceps, gently raise cotton plug
noted on the product sheet. Viral growth medium
is usually supplemented with a lower percentage
of serum than cell growth medium, often ranging
between 2-10% depending on the virus (See NOTE
1). Ensure that both the cell and viral growth media
are equilibrated for temperature and pH.
2. Initiate the recommended production host, and

Phone 800.638.6597 www.atcc.org page 2

Getting Started with an ATCC Viral Strain
grow the monolayer to an appropriate confluency.
NOTE 1:
3. Prior to thawing the frozen virus stock, check the virus titer listed on Viral growth medium prepared
the lot specific certificate of analysis to determine the amount of virus for tissue culture-adapted strains
of Influenza should not be
needed. Thaw the vial of frozen virus via gentle agitation in a water supplemented with FBS.
bath set at 37°C. Thawing will be rapid (approximately 2 minutes or
until all ice crystals have melted).
4. Remove the vial from the water bath and decontaminate the outer surface using 70% ethanol. Follow
strict aseptic conditions in a biological safety cabinet for all further manipulations.
5. Prepare the viral stock in base medium (without serum) unless specified.
6. Remove the cell growth medium from the cell culture, wash the monolayer of cells once or twice with
PBS, and inoculate with the prepared viral stock to provide an optimal multiplicity of infection (MOI) as
indicated on the product sheet, if applicable.
7. Propagate the virus according to the recommended infection conditions as described on the product
sheet. For additional information, refer to the chapter Viral Growth and Propagation.
Strains Propagated in Chicken Eggs
1. In advance, prepare chicken eggs by incubating eggs under the recommended temperature and
atmospheric conditions. Additionally, all eggs should be candled to ensure viability and properly
developed embryos. Healthy embryos will have an air sac, well-developed blood vessels, and
observable movement.
2. Prior to thawing the frozen viral preparation, check the certificate of analysis for lot specific titer
information. Thaw the frozen virus vial via gentle agitation in a water bath set at 37°C. Thawing will be
rapid (approximately 2 minutes or until all ice crystals have melted).
3. Remove the vial from the water bath and decontaminate the outer surface using 70% ethanol. Follow
strict aseptic conditions in a biological safety cabinet for all further manipulations.
4. Inoculate eggs using the inoculation procedure described in the chapter Viral Growth and Propagation.

Initiating Lyophilized Cultures

1. Open vial according to enclosed instructions. Instructions are also available on the ATCC website, www.
atcc.org, within the technical bulletin, “How to Revive Cultures”.
2. Aseptically add an appropriate volume of sterile double-distilled water at room temperature. Mix well.
3. Dilute the sample in base medium (without serum) unless specified, and inoculate host cells to provide
an optimal MOI as indicated on the product sheet, if applicable.

page 3 www.atcc.org Email [email protected]

 Viral Replication and Propagation
Viral Replication and Propagation

Propagation Host Range

For tissue culture-adapted strains, the appropriate selection and processing of cell cultures is important
for successful viral isolation, titer, and infectivity². Typically, viruses can only infect a limited number of
hosts, known as the host range. This is best explained by a “lock and key” mechanism as certain proteins
on the viral surface must fit specific receptor sites on the host cell surface. When using ATCC viral strains,
the recommended host is indicated on the provided product sheet. For customer convenience, ATCC Cell
Biology holdings include cell lines for the propagation of viruses (Table 1, Appendix).
Table 1: Examples of propagation hosts for tissue culture-adapted viruses

ATCC® No. Product Name ATCC® No. Propagation host

53592™ Chlamydophila pneumonia* CCL-23™ HEp-2
VR-129B™ Encephalomyocarditis CCL-81™ Vero
Human herpesvirus 4
VR-1492™ N/A B95-8
(Epstein-Barr virus)
VR-260™ Humans herpesvirus 1 CCL-81™ Vero
VR-734™ Human herpesvirus 2 CCL-81™ Vero
VR-1367™ Human herpes 3 CCL-171™ MRC-5
VR-538™ Human herpesvirus 5 CCL-171™ MRC-5
VR-93™ Human parainfluenza CCL-7.1™ LLC-MK2 Derivative
Human respiratory
VR-26™ CCL-23™ HEp-2
syncytial virus
Human respiratory
VR-1540™ CCL-23™ HEp-2
syncytial virus
Human respiratory
VR-1580™ CCL-23™ HEp-2
syncytial virus
VR-283™ Human rhinovirus 16 CRL-1958™ H1-HeLa
VR-95™ Influenza A virus (H1N1) N/A SPF CE
VR-897™ Influenza A virus (H1N1) N/A SPF CE
VR-1469™ Influenza A virus (H1N1) CCL-34™ MDCK
VR-1520™ Influenza A (H1N1) CCL-34™ MDCK
VR-544™ Influenza A virus (H3N2) N/A SPF CE
VR-1679™ Influenza A virus (H3N2) CCL-34™ MDCK
VR-1535™ Influenza B virus CCL-34™ MDCK
VR-1583™ JC polyomavirus CRL-1651™ COS-7
*For historical reasons and because of similar requirements for handling, Chlamydia and Rickettsia are included in this guide

Phone 800.638.6597 www.atcc.org page 4

Viral Replication and Propagation
Viral Propagation
Propagation in Cell Culture
A number of ATCC viruses are propagated in cell culture. Typically, propagation hosts are grown in tissue
culture vessels (such as T flasks) using media and reagents specified for the host cell line. Most cell lines are
seeded the day prior to setting up an infection and should not be seeded more than two days in advance,
nor passaged more than 9 times prior to infection. In addition to setting up cells for infection, negative
control cells should also be set up to monitor cellular health.
1. Identify the recommended propagation host as indicated on the product sheet. Plan to use the
propagation host.
2. Prepare the cell growth medium for growing the host cell line.
3. Prepare the virus growth medium as recommended on the product sheet.
4. One to two days prior to inoculation seed the host cells. Be sure to include a vessel that will not be
inoculated with virus to serve as a negative control.
5. Allow cells to reach the appropriate confluency. (See NOTE 2) NOTE 2:
The required confluency of the host
6. Prior to thawing the frozen virus stock check the virus titer listed on cell line will differ between viruses.
the certificate of analysis. Quickly thaw the virus in a 37˚C water bath.
7. Dilute the virus stock in the appropriate volume of viral growth medium.
8. Remove the cell growth medium from the cell culture flasks.
9. Inoculate the diluted virus to provide an optimal MOI as indicated on the product sheet.
10. Incubate tissue cultures under the appropriate temperature and atmospheric conditions for the
recommended incubation period.
11. After the recommended incubation time period, check the flask for cytopathic effects (CPE) when
applicable.

Propagation of Feline infectious peritonitis virus (ATCC® No. VR-2004™) in CRFK cells (ATCC®
No. CCL-94™). The panel on the left are uninfected CRFK cells. The panel on the right are
infected CRFK cells exhibiting CPE.

Propagation in Chicken eggs

Several ATCC virus holdings, such as influenza, are propagated in embryonated chicken eggs. There are
many advantages to culturing in eggs, including easy care, quick viral replication, and an inherently aseptic
environment. When culturing in embryonated eggs, ensure that eggs are viable, have properly developed
blood vessels and air sacs and are obtained from pathogen-free flocks. Depending on the virus, different
inoculation routes and/or organs may be used to cultivate the agent. These include the allantoic cavity, the
amniotic cavity, the chorioallantoic membrane (CAM), and the yolk sac (Table 2). Below, we describe the
procedures for allantoic cavity, amniotic cavity, and CAM inoculation. For the following procedures, ATCC

page 5 www.atcc.org Email [email protected]

 Viral Replication and Propagation
recommends performing viral inoculation and harvest Chorioallantoic Amniotic
cavity
within a biological safety cabinet. For additional membrane Chorioallantic
membrane inoculation
information on the inoculation or propagation of Shell

embryonated eggs, contact ATCC technical services.

Amniotic
inoculation
A. Allantoic Cavity Inoculation Allantoic
Air
inoculation
1. For allantoic cavity inoculation, most sac
Yolk sac
viruses require 10-day old embryos. While
candling the eggs, draw a pencil line
Shell
around the air sac. Using an 18.5 gauge membrane Yolk sac
inoculation
needle, poke a hole into the air sac. Albumin Allantoic
cavity
2. Using a 1.0 mL syringe fitted with a 22.5
gauge needle, inject the viral inoculum through the hole, into the allantoic cavity, being
careful not to stick the embryo.
3. Seal the hole with tape or wax.
4. Incubate the inoculated eggs under conditions recommended for viral replication. Candle
eggs 12-18 hours after inoculation and discard eggs that are non-viable.
5. To harvest allantoic fluid, refrigerate eggs for at least 2 hours post-incubation. Once the
embryo is no longer viable, open the egg by tapping on the shell just above the air sac until
the shell breaks.
6. Use sterile scissors to cut away the shell around the air sac.
7. Aspirate the allantoic fluid with a syringe or a pipette. Usually 5 mL can be harvested from each
egg; this is considered infectious material.
B. Amniotic Cavity Inoculation
1. While candling the eggs, make a small hole in the side of the egg. Create the hole slowly as it
is easy to accidently stick the embryo.
2. Using a 1.0 mL syringe, insert the needle and syringe containing the viral inoculum into the
egg until the amniotic sac moves slightly. The needle is then thrust through the membrane
and the fluid is injected slowly.
3. Immediately seal the hole in the shell with tape or wax.
4. Incubate the inoculated eggs under conditions recommended for viral replication.
5. Candle eggs 12-18 hours after inoculation and discard eggs that are non-viable.
6. To harvest amniotic fluid, refrigerate eggs for at least 2 hours post-incubation. Once the
embryo is no longer viable, open the egg by tapping on the shell just above the air sac until
the shell breaks.
7. A needle and syringe must be used to aspirate the fluid. The needle may be inserted directly
into the amniotic sac, or the embryo may be carefully removed from the egg and placed in a
petri dish. Typically, one embryo will yield about 1.0 mL of fluid.
C. Chorioallantoic Membrane (CAM) Inoculation
1. Mark an area free from large blood vessels on the side where the embryo is located and the
area over the air sac.
2. Make one hole on the side and one over the air sac. Puncture the shell taking care not to
damage the CAM.
3. Gently apply suction to the hole over the air sac. Do this over an egg candler to see the CAM
drop and the new air sac form.

Phone 800.638.6597 www.atcc.org page 6

Viral Replication and Propagation
4. Add 1.0 mL of the viral inoculum on the dropped membrane and rotate the egg to distribute
the inoculum over the membrane.
5. Seal the hole with nail polish.
6. Candle inoculated eggs daily. Any embryos that die within 24 hours should be discarded.
7. To harvest, refrigerate eggs for at least 2 hours. Once the embryo is no longer viable, make a
tape handle over the area of inoculation. To do so, cut a piece of tape, without joining either
end, join the middle of the piece together leaving both ends free to adhere to the egg shell
with a middle piece that is no longer sticky, forming a handle sticking up from the egg shell.
8. Cut off the top half of the eggshell, including the infected area, and gently remove the CAM,
which is attached to the shell.
9. Place the infected CAM in a tissue culture dish with PBS, spread the membrane flat against the
dish, and place the dish on a dark surface to facilitate counting of pocks.
Table 2: Examples of ATCC viruses propagated in embryonated chicken eggs

Optimal
Product Name Egg Age (Days) Inoculation Route Incubation (Days) Death of Embryo
Temperature (˚C)
Influenza A virus 10-11 Allantoic 2-3 33-35 -
Influenza B virus 10-11 Allantoic 2-3 33-35 -
Sendai virus 10-11 Allantoic 2-3 35-37 +
Rabies virus 7 Yolk 9-10 36.5 -

Propagation of Common Viruses and Chlamydia

Human herpesvirus 4 (Epstein-Barr Virus)
Epstein-Barr virus (EBV) is a universal human pathogen commonly transmitted via saliva³. Primary infections
among adolescents and young adults result in mononucleosis, a condition characterized by fever and the
swelling of lymph tissues. Following infection, EBV remains in a latent stage in most adults. In rare cases, the
virus may reactivate and contribute to neoplastic disorders such as Burkitt’s lymphoma or post-transplant
lymphoproliferative disorder (PTLD)⁴. To propagate EBV, the virus is often harvested from tumors growing
on patients with Burkitt’s lymphoma, or obtained from a biological resource center such as ATCC, and
further grown in human lymphoblastoid cells.
ATCC® No. VR-1492™, VR-603™, VR-602™
Recommended Host: Human lymphoblastoid cells
Preparation: Infected tissue culture with DMSO and FBS
Incubation: 5-15 days at 37°C
Atmosphere: 5% CO₂ in an air atmosphere
Effect: Polykaryocyte formation and cell swelling
Influenza
Influenza viruses are highly contagious, enveloped, airborne pathogens that cause acute febrile illness,
fatigue, and respiratory infection. There are three types of influenza including influenza A, B, and C, which
are distinguished by the presence of specific, core nucleoproteins. Of these viral types, influenza A is
considered the most pathogenic. To propagate influenza, the virus is often cultured in the allantoic fluid of

page 7 www.atcc.org Email [email protected]

 Viral Replication and Propagation
embryonated chicken eggs. However, some strains are propagated
in amniotic fluids or have been adapted for growth in tissue culture.
ATCC® No. VR-1469™, VR-95™, VR-1520™, VR-544™, VR-897™,
VR-1679™, VR-1807™, VR-1811™, VR-1813™
Recommended Host: Pathogen-free embryonated
chicken egg, 10-11 days old, or MDCK cells (ATCC® No.
CCL-34™)
Image of Influenza courtesy of Dr. Erskine L
Preparation: Infected chicken egg allantoic fluid, infected Palmer and ML Martini, CDC
tissue culture
Incubation: 2-3 days at 34°C for influenza propagated in chicken eggs (CE), 33-35˚C for influenza
propagated in tissue culture (TC). Harvest when CPE has progressed throughout the monolayer.
Atmosphere: An air atmosphere for CE, 5% CO₂ atmosphere for TC. CO2 level is determined by
media formulation.
Effect: Hemagglutination of chicken red blood cells, cell rounding sloughing in tissue culture.
Respiratory Syncytial Virus
Respiratory syncytial virus (RSV) is a major cause of respiratory
illness in young children, resulting in pneumonia and bronchiolitis.
In adults, RSV often manifests symptoms similar to the common
cold. This virus is commonly transmitted when droplets containing
the virus are aerosolized by coughing or sneezing.
ATCC® No. VR-1540™, VR-1540P™, VR-26™, VR-1580™, VR-
1803™
Recommended Host: HEp-2 (ATCC® No. CCL-23™) and
Image of Respiratory Syncytial Virus courtesy of
HeLa (ATCC® No. CCL-2™) cells Dr. Craig Lyerla, CDC
Preparation: Infected tissue culture fluid and cell lysate
Incubation: 5-12 days at 37˚C
Atmospherte: 5% CO₂ in an air atmosphere
Effect: Syncytia formation
Chlamydia
Species within the Chlamydia genus are obligate intracellular bacterial pathogens commonly transmitted
through sexual activity. Common symptoms associated with Chlamydia species include conjunctivitis,
pelvic inflammatory disease, and infection of the reproductive organs. These bacterial species are
commonly categorized with viruses as they have similar propagation properties. Often it is recommended
that the Chlamydia stock be sonicated first before inoculating cells, and infection may be enhanced by
centrifugation after inoculation. Follow the specific instructions on the product sheet for preparing the
cells.
ATCC® No. VR-123™, VR-346™, VR-347™, VR-573™, VR-879™, VR-885™, VR-886™, VR-887™
Recommended host: McCoy cells (ATCC® No. CRL-1696™)
Preparation: Infected tissue culture fluid and cell lysate
Incubation: 2-3 days at 35-37˚C
Atmosphere: 5% CO₂ in an air atmosphere
Effect: Intracellular inclusion bodies visualized by fluorescent staining with genus or species
specific conjugated monoclonal antibodies.

Phone 800.638.6597 www.atcc.org page 8

Viral Replication and Propagation
Viral Titering
Plaque Assay
Calculating viral titer is necessary in order to determine viral infectivity. This
can be determined by a plaque assay or through calculating the infectious
dose. The plaque assay was initially developed to count and measure the
infectivity level of bacteriophages. This technique has since been modified
for use in animal virology, and has been a reliable determination of titer
for a number of tissue culture-adapted viruses. The basis of this assay is
to measure the ability of a single infectious virus to form a plaque on a
cell culture monolayer. A plaque is developed as part of the viral infection
cycle, where following viral replication, the host cell dies⁵.
1. Grow the host cells in wells with the recommended growth medium
for the cell line. Allow the cells to reach the appropriate confluency. Plaque assay of a tissue culture-
adapted viral strain.
2. Remove the growth medium and wash with Dulbecco's Phosphate-
Buffered Saline (DPBS). Add diluted virus to each well, using multiple wells per dilution.
3. Incubate dishes for 1-2 hours to allow for viral adsorption.
4. Remove the inoculum and wash with basal medium, if applicable.
5. Overlay the cells with overlay medium. Incubate for a length of time
appropriate for infection. Remove overlay, if applicable. NOTE 3:
This is a general procedure used
6. Observe the cell monolayers daily for the presence of foci or plaques to determine the potency of a
7. Count the number of plaques on plates with 20 or more plaques. virus. Please refer to the following
references for more details on
The average amount of plaques per Petri dish multiplied by the virus this procedure: A Manual of Basic
dilution gives the number of plaque forming units (PFU) per volume Virological Techniques, published
of inoculum. This number may be expressed as the titer of the virus. by Prentice-Hall Inc. , or Virology
1

Methods Manual, published by

(See NOTE 3) Academic Press. (1996) 5.

Tissue Culture Infectious Dose (TCID)

Viral titer can be determined in vitro by calculating the infectious dose. For tissue culture-adapted strains,
this calculation is ascertained through an endpoint dilution assay in cell culture. The most reproducible
endpoint of the dilution assay is the dilution of the virus that will produce a pathological change in 50%
of the cell cultures inoculated. This number is expressed as 50% the infectious dose, or TCID₅₀, which is
analogous to the calculation for lethal dose 50. The accuracy of this method is related to the number of
replicates at each dilution⁵.
1. Prepare a cell culture plate with the recommended cell line for viral propagation (preferably the same
cells that the virus being tested was grown in).
2. Incubate the plate under the appropriate conditions for cell growth until cells reach an optimum
density for infection.
3. Prepare viral dilutions in base medium.
4. Remove cell growth medium from plate, the monolayer may be washed with remove any inhibitory
agents.
5. Inoculate at least 3 wells with each dilution. Be sure to inoculate wells with base medium to serve as
negative controls. Use a fresh, sterile pipette for each dilution.
6. Allow the plate to incubate for 1 to 2 hours under conditions suitable for virus adsorption.

page 9 www.atcc.org Email [email protected]

 Viral Replication and Propagation
7. Add viral growth medium and incubate the plate under conditions suitable for the virus and observe
all wells daily. Record results for each well daily.
8. The endpoint is determined when the CPE or immunofluorescence assay (IFA) read-out appear the
same per dilution for 3 separate readings.
9. The titer is calculated using the method of Reed and Muench⁶. A titer expressed as 10(3.0)TCID₅₀/0.2 mL
in 3 days in XXXX cell line may be translated as: 0.2 mL of virus diluted at 1:1000 will infect 50% of the
cells in 3 days when using XXXX cell line. (See NOTE 3)
The TCID₅₀ can be converted to plaque forming units (PFU) using the Poisson distribution. This conversion
is an estimate based on the rationale that the limiting dilution, which would infect 50% of the cell layers
challenged, would be expected to produce a single plaque in a cell monolayer. However, ATCC recommends
that the actual number of PFUs be determined empirically.
To estimate PFU from TCID₅₀, the Poisson distribution can be applied; P(o) is the proportion of negative tubes
and ‘m’ is the mean number of infectious units per volume (PFU/mL), P(o)=e(-m). For any titer expressed as
TCID₅₀, P(o)=0.5. Thus, e(-m)=0.5 and m= -ln 0.5, which is ≈0.7. Therefore, one could multiply the TCID₅₀ titer
(per mL) by 0.7 to predict the mean number of PFU/mL. For example, one can assume that material with
a TCID₅₀ of 1x10⁵ TCID₅₀/mL will produce approximately 0.7x10⁵ PFU/mL. When applying this calculation,
remember that the estimated mean will only be valid if the changes in the protocol required to visualize
plaques do not alter viral expression as compared to conditions used to determine TCID₅₀.
Chicken Embryo Infectious Dose (CEID)
For viruses normally propagated in chicken eggs, such as influenza virus, viral titer is calculated as the chicken
embryo infectious dose (CEID). Viral cultures are serially diluted and are used to inoculate embryonated
chicken eggs. Following incubation, allantoic fluid is harvested from each egg at all dilutions and virus titer
is determined by the appearance of hemagglutination. A positive hemagglutination reaction indicates the
virus is present at that dilution.
1. Order embryonated chicken eggs of the proper age, 8-12 days old depending on the virus. When the
eggs arrive, place them in an incubator at an appropriate temperature with a dish of water close by to
provide moisture to prevent the eggs from drying out.
2. When you are ready to inoculate, candle the eggs to locate the air sac
NOTE 4:
and embryo. Using a pencil, outline the air sac area and indicate where A viable egg has a series of small
the embryo’s eye is located. In a biological safety cabinet, punch a hole blood vessels within the allantoic
into the shell within the defined air sac area, on the opposite side of membrane, which can be seen
during candling. Additionally, the
the egg from the embryo’s eye. Inoculate the allantoic fluid of each embryo’s eye will look like a black
egg with the serial dilution of virus. Seal the hole with nail polish and spot, which will move.
incubate the eggs near a pan of water at the proper temperature as
recommended on the provided product sheet. (See NOTE 4)
3. Candle the eggs 24 hours post-inoculation to check for viral-induced death. Place any of the dead eggs
into a biohazard bag, seal the bag with autoclave indicator tape and refrigerate to await autoclaving.
Return the rest of the eggs to the incubator.
4. Following the recommended incubation period, harvest the virus. Depending upon the virus, death of
the embryo may have occurred. By this time, a viable embryo will have grown much larger, will be more
active, and the network of blood vessels will be more visible. A dead embryo will not move and the
egg may or may not be as transparent and the blood vessels will have mostly disappeared. For viable
embryos, sacrifice the embryo prior to viral harvesting by placing the egg at 4°C for at least 2 hours.
5. Prepare a 0.5% suspension of chicken red blood cells using phosphate buffered saline (PBS) while the
infected eggs are chilling in a biological safety cabinet. Use sterile forceps to break the top of the shell

Phone 800.638.6597 www.atcc.org page 10

Viral Replication and Propagation
open and pull back the allantoic membrane. Place all egg fragments, including parts of the shell into
a double biohazardous materials bag. Harvest the allantoic fluid from each egg by using a pipette to
collect the fluid into a different well of a rounded-bottom 96 well plate for each egg, being sure to use
a new pipette for each dilution.
6. Add a 1:1 ratio of the 0.5% red blood cell suspension to allantoic fluid in each tube. Mix by gently
tapping and allow the red blood cells to settle to the bottom of the wells. After 30-45 minutes at room
temperature, read the hemagglutination assay by recording
the presence of a button of cells or the presence of a lattice
formation at the bottom of the tube. A negative result is seen
by the button of red blood cells at the bottom of the rounded
well. A positive result is seen by the formation of the lattice
formation at the bottom of the rounded well. Once the results
are properly recorded, place the plate in a biohazard bag to
await proper decontamination.
7. The end point is taken to be the highest dilution of virus
suspension that produces a positive result. HA = 1:640 means Hemagglutination assay depicting Influenza B
that the virus was titered by a hemagglutination assay (HA) virus (ATCC® No. VR-295™) at dilutions varying
and the endpoint for the assay was a dilution of 1:640. (See from 10¯⁹ to 10¯¹.
NOTE 3 ) Left column = Negative control
Columns 2-10 = Dilutions 10¯⁹ to 10¯¹
Column 11 = Positive control

page 11 www.atcc.org Email [email protected]

 Growth Media for Tissue Culture-Adapted Viruses
Growth Media for Tissue Culture-Adapted Viruses

Media for Culturing Propagation Hosts

For the propagation of tissue culture-adapted viruses, it is important to grow and maintain the host cell line
in an appropriate medium. The recommended media for all host cells is indicated on the product sheet for
the host cell line and can also be found online at www.atcc.org.
Cell culture media are complex mixtures of salts, carbohydrates, vitamins, amino acids, metabolic precursors,
growth factors, hormones, and trace elements. The requirements for these components vary among cell
lines. Carbohydrates are supplied primarily in the form of glucose. In some instances, glucose is replaced
with galactose to decrease lactic acid build-up, as galactose is metabolized at a slower rate. Other carbon
sources include amino acids (particularly L-glutamine) and pyruvate.
In addition to nutrients, the medium helps maintain the pH and osmolality in a culture system. The pH
is maintained by one or more buffering systems; CO₂/sodium bicarbonate, phosphate, and HEPES
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) are the most common. Sera will also buffer a complete
medium. Phenol red, a pH indicator, is added to the medium to colorimetrically monitor changes in pH.
Media commonly used in the propagation of tissue culture-adapted strains include the following:
Eagle’s Minimum Essential Medium (EMEM) ATCC’s modification of EMEM (ATCC® No. 30-2003) contains
Earle’s balanced salt solution, non-essential amino acids, L-glutamine, and sodium pyruvate. It is formulated
with a reduced sodium bicarbonate concentration (1,500 mg/L) for use with 5% CO₂. Because EMEM is a
simple medium, it is often fortified with additional supplements or higher levels of serum.
Dulbecco’s Modified Eagle’s Medium (DMEM) has roughly twice the concentration of amino acids and four
times the amount of vitamins as EMEM, as well as ferric nitrate, sodium pyruvate, and some supplementary
amino acids (though not all nonessential amino acids). The original formulation contained 1,000 mg/L of
glucose, but in the more commonly used variations this amount was increased to 4,500 mg/L. ATCC DMEM
(ATCC® No. 30-2002) has 4,500 mg/L of glucose and a reduced
sodium bicarbonate concentration (1,500 mg/L) for use with 5%
CO₂.
RPMI-1640 ATCC’s RPMI-1640 (ATCC® No. 30-2001) was modified to
contain higher amounts of glucose (4,500 mg/L), sodium pyruvate,
and HEPES buffer. It also contains a reduced concentration of
sodium bicarbonate (1,500 mg/L) for use with 5% CO₂.
Leibovitz’s L-15 Medium (ATCC® No. 30-2008) is formulated for
free gas exchange with atmospheric air. The standard sodium
bicarbonate/CO₂ buffering system is replaced by a combination of
phosphate buffers, free-base amino acids, higher levels of sodium pyruvate, and galactose. A CO₂ and air
mixture is detrimental to cells when using this medium for cultivation. However, cell cultures can be grown
in CO₂ incubators with L-15 medium provided there is no exchange between the air in the culture vessel
with that of the incubator (i.e., caps of flasks are tightly closed).
VeroPlus SFM (ATCC® No. ACS-4001) is a defined, serum-free, animal component-free medium that contains
inorganic salts, vitamins, amino acids, glucose, and phenol red. VeroPlus SFM should be supplemented with
L-glutamine (ATCC® No. 30-2214) prior to use.

Phone 800.638.6597 www.atcc.org page 12

Growth Media for Tissue Culture-Adapted Viruses
Media Formulations
The formulations for media used by ATCC can be found online. Please note that there are cell lines in the
collection used for viral propagation that may require media that is not currently sold by ATCC.

Media Supplements
The growth media recommended for host propagation may require the addition of components not
already available in the base medium. These components may include hormones, growth factors, or serum.
After supplements have been added to the base medium, the shelf life of the medium should be determined
on a case-by-case basis. Media containing serum, antibiotics, and/or antimycotics tend to degrade faster
than base media alone. Media containing supplements should not be frozen as this may cause certain
compounds to precipitate out of solution; media should be stored at 2°C to 8°C. For additional information
regarding the preparation, storage, or usage of specific additives, contact your local supplier or consult with
the manufacturer’s product information sheet.
Serum
Serum can serve as a source of growth factors, proteins, vitamins, hormones,
carbohydrates, lipids, amino acids, minerals, and trace elements. The exact
composition of serum is unknown and varies from lot to lot, although lot-
to-lot consistency has improved in recent years.
Sera from fetal bovine sources are commonly used to maintain cell cultures
in preparation for viral infection. Fetal serum is a rich source of growth
factors and is appropriate for the growth of fastidious cells. It is often
supplied at a concentration of 2-10%. (See NOTE 5)
Unfortunately, naturally derived products from animals, such as sera, may
contain adventitious microorganisms. All reputable suppliers routinely
test their products for infectious viruses by several methods including NOTE 5:
Fo r v i r a l i n o c u l a t i o n , ATCC
fluorescent antibody labeling, cytopathic effect, and hemadsorption. recommends decreasing the
These products are also screened for the standard microbial contaminants percentage of serum to 2% as it can
such as bacteria, fungi, and mycoplasma. To reduce the risk of any possible interfere with viral attachment. This
can vary from strain to strain, and is
contamination, ATCC recommends that all serum should be triple filtered not applicable for influenza viruses.
through 0.1 µm sterile filters before use.
ATCC offers the following types of animal sera:
• Fetal Bovine Serum (also known as fetal calf ) – ATCC® No. 30-2020
• Fetal Bovine Serum qualified for embryonic stem cells – ATCC® No. SCRR-30-2020
• Iron-supplemented Calf Bovine Serum – ATCC® No. 30-2030
• Horse Serum – ATCC® No. 30-2040
These products are rigorously tested for adventitious infective agents and sourced only from U.S. herds.
Further, each lot is tested for its ability to support cell culture growth and is the same sera used in ATCC labs.
A. Storage
Do not store serum at temperatures above -20°C for any length of time. Avoid any repeated freeze-
thaws by dispensing and storing sera in aliquots. Additionally, ensure that sera are stored away
from direct light.

page 13 www.atcc.org Email [email protected]

 Growth Media for Tissue Culture-Adapted Viruses
B. Thawing
The following procedure is used to thaw serum:
1. Place the frozen serum in a refrigerator at 2°C to 8°C overnight.
2. Put the bottles in a 37°C water bath and gently agitate occasionally to mix the solutes that
tend to concentrate at the bottom of the bottle.
Do not keep the serum at 37°C any longer than necessary to thaw it, and do not thaw the serum
at higher temperatures. Thawing serum in a bath above 40°C without mixing may lead to the
formation of a precipitate inside the bottle.
C. Turbidity and precipitates
All sera may retain some fibrinogen. Because external factors may initiate the conversion of
fibrinogen to fibrin, flocculent material or turbidity may be observed after the serum is thawed.
The presence of this material does not alter the serum’s performance. If the presence of flocculent
material or turbidity is a concern, it can be removed by filtration through a 0.45 µm filter.
A precipitate can form in serum when incubated at 37°C or higher for prolonged periods. This
is often mistaken for microbial contamination. This precipitate may include crystals of calcium
phosphate, but this does not alter the performance of the serum as a supplement. Heat inactivation
of sera can also cause the formation of precipitates.
Additives and Cryoprotectants
To preserve viral strains by cryopreservation, ATCC may use a mixture of FBS and DMSO (ATCC® No. 4-X) or
glycerol. Some viruses require a specialized mixture of cryoprotectants or additives. For more information,
refer to the cryopreservation section of the chapter entitled Preservation.

Phone 800.638.6597 www.atcc.org page 14

Preservation
Preservation
There is no single procedure that is optimal for the preservation of all animal viruses. Both the type of agent
and recommended growth conditions of the culture influence the method of cryopreservation, and the
determination of these ideal conditions may require some experimentation. There are many advantages of
preservation that far outweigh the required investment in equipment and reagents for continuous in vitro
expansion. These advantages include:
• Overall safety of viral stocks against loss due to equipment failure or contamination by other microbial
organisms.
• Elimination of time, energy, and material costs associated with the maintenance of viral strains not
currently in use.
• Insurance against phenotypic drift due to genetic instability and/or selective pressures.
• Creating a standard reagent that can be used for a series of experiments.
The methodologies used at ATCC have proven successful for a large number of organisms. Currently, ATCC
only uses cryopreservation methods to preserve viral strains. However, several viral strains in the collection
are available as freeze-dried (lyophilized) cultures. The basic methodology for the cryopreservation and
lyophilization of viruses are described in the subsequent sections. For historical reasons and because of
similar requirements for handling and preservation, Chlamydia and Rickettsia species are also included here.

Cryopreservation
Overview
Freezing a viral suspension often results in a decrease in viability and titer¹¹, ¹². For cell-associated pathogens,
such as Chlamydia and Rickettsia, as the suspension is cooled below the freezing point, ice crystals begin to
form and the concentration of solutes in the suspension increases resulting in damage of host cell structures.
This can be minimized if water within the cells is allowed to escape by osmosis during the cooling process;
a slow cooling rate, generally -1˚C to -10˚C per minute, facilitates this progression. However, as host cells
lose water, they shrink in size and will quickly lose viability if they surpass a minimum threshold volume.
The addition of cryoprotectant agents, such as glycerol or dimethylsulfoxide (DMSO), will mitigate these
effects¹³, ¹⁴.
The viability of viruses that are not cell-associated is best maintained by rapid freezing. In this method,
samples are quickly frozen in a dry ice slurry and stored in liquid nitrogen vapor or within a mechanical
freezer at -80°C.
Overall, there are numerous factors that can affect the viability of recovered viruses. These critical parameters
can include the composition of the cryoprotectant and the viral titer. For cell-associated viruses, obtain
optimal cell viability upon recovery by modifying the cryopreservation procedure for each viral strain.
Contact ATCC for more information on the cryopreservation of viral strains.
Freeze Medium
Glycerol and DMSO are the most common cryoprotectant agents. To preserve viral strains, ATCC commonly
uses a mixture of FBS and DMSO or glycerol. When employing these cryoprotectants, use only reagent-
grade DMSO or glycerol. Store both in aliquots protected from light. ATCC offers DMSO (ATCC® No. 4-X) that
has been thoroughly tested for use.

page 15 www.atcc.org Email [email protected]

 Preservation
Some viruses require specialized preservation methods. Several representative strains with unique
preparations are listed in Table 3; however, these examples and methods may not be applicable to all
members of the group. Overall, the optimum formulations for individual viral strains must be determined
empirically.
Table 3: Examples of Frozen Preparations

ATCC® No. Product Name Preparation

VR-1™ Human adenovirus 1 Infected culture medium
VR-343™ Japanese encephalitis virus Infected culture medium diluted 1:1 with calf serum
VR-977™ Human herpesvirus 5 Infected culture medium (EMEM + 10% FBS + 7% DMSO)
VR-897™ Influenza A virus (H1N1) Infected allantoic medium
VR-955™ Human respiratory syncytial virus Infected culture medium (EMEM + 2% FBS)
VR-129B™ Encephalomyocarditis virus Infected culture medium (MEM +2% FBS)
VR-838™ Raccoonpox virus Infected culture medium (EMEM + 2% FBS)
VR-156™ Vaccinia virus Infected culture medium (L-15 + 2% FBS + L-glut)
VR-659™ Rous sarcoma virus Infected culture medium (M199)
VR-137™ Rabies street virus 10% infected mouse brain suspension in PBS + 10% horse serum
VR-612™ Rickettsia akari Infected yolk sac diluted 1:1 in sucrose-phosphate glutamate

Equipment
A. Cryopreservation vials
There are two materials to choose from for cryopreservation vials: glass or plastic. Glass vials are
more difficult to work with: they need to be sterilized before use, they need to be sealed with a
hot flame, and they can be difficult to open. However, they are considered fail-safe once properly
sealed.
If cryopreservation in glass ampoules is not possible, plastic vials can be used. Plastic vials come in
two varieties: those with an internal thread and silicone gasket, and those with an external thread.
Vials with an internal-thread were the first commercially available, but have some disadvantages
over the external-thread version. For example, while the silicone gasket provides an excellent seal,
it needs to be tightened just right; the vial will leak if the seal is too tight or too loose.
B. Controlled-rate freezing chambers
For cell-associated viruses, there are several means to achieve a cooling rate of -1˚C per minute.
The best method involves the use of a computer controlled, programmable electronic freezing
unit (such as Thermo Scientific* CryoMed Freezers), which rigorously maintains this rate of cooling.
This is the method used exclusively at ATCC. Such equipment is relatively expensive and necessary
for only the most sensitive strains.
A less costly approach is to place the cryopreservation vials into an insulated chamber and cool
for 24 hours in a mechanical freezer at -70˚C or colder. There are several commercially available
freezing chambers, which achieve a cooling rate very close to the ideal -1˚C per minute (CoolCell®
LX; ATCC® ACS-6000). Alternatively, the vials can be placed into a polystyrene box, with 15 mm
(3/4 inch) thick walls and 1 L capacity that is packed with paper, cotton wool, or foam peanuts for
insulation.

Phone 800.638.6597 www.atcc.org page 16

Preservation
Liquid Nitrogen Freezing Storage
The ultra-low temperatures (below -120˚C) required for long-term
storage can be maintained by specialized electric freezers, or more
commonly, by liquid nitrogen freezers. There are two basic types
of liquid nitrogen storage systems: immersing vials in the liquid or
holding vials in the vapor phase above the liquid. The liquid-phase
system holds more nitrogen and thus requires less maintenance.
However, there is always a chance that some liquid will enter
improperly sealed vials, which may then explode when retrieved.
For this reason, ATCC strongly recommends storage in the vapor-
phase.
Vapor-phase storage systems create a vertical temperature gradient within the container. The temperature
in the liquid nitrogen at the bottom will be -196˚C, whereas the temperature at the top will vary depending
upon the amount of liquid nitrogen at the bottom and the length of time the container is opened. To ensure
the safe storage of cells, maintain sufficient levels of liquid nitrogen in the container so that the temperature
at the top is -120˚C or colder. All storage systems should be equipped with temperature alarms.
Cryopreservation Procedure
A. Uncontrolled Freezing
The viability of most viruses is best maintained by fast freezing after harvesting. Dispense the
material into ampoules, place the ampoules in a rack, and dip in a dry ice/ethanol bath. Store the
frozen material in liquid nitrogen vapor or in a mechanical freezer at -80°C.
B. Controlled Freezing
To preserve cell-associated pathogens, such as Chlamydia and Rickettsia, a controlled freeze is
preferred.
1. Incubate the viral agent under the recommended conditions until a maximum yield is obtained
(maximum cytopathic effect if applicable).
2. Add a cryoprotective agent to the viral suspension. For many viral strains, this will be a mixture
of FBS and DMSO or glycerol. Some strains may require specialized conditions, examples of
these can be found in Table 1.
3. Within a biological safety cabinet, dispense 0.5 to 1.0 mL of the above mixture into sterile
plastic cryovials or glass ampoules. Store the filled glass ampoules on ice prior to sealing. Glass
ampoules can be sealed using a gas-oxygen torch, pulling the neck of the ampoules as it is
rotated in the flame. Following sealing, disinfect glass ampoules by spraying with disinfectant.
4. Place the vials into a pre-cooled (4°C), controlled-rate freeze chamber and place the chamber
in a mechanical freezer at -70°C (or colder) for at least 24 hours. Alternately, use a pre-cooled
(4°C) programmable freezer unit set to cool the vials at -1°C per minute until a temperature
below -40°C is achieved and then set the temperature to abruptly drop to -120°C.
5. Quickly transfer the vials to a liquid nitrogen or -120°C freezer. Frozen material will warm up
above -50°C.
6. Record the location and details of the freeze.
7. After 24 hours at -120°C, remove one vial, appropriately restore the viral strain, and determine
the viability and sterility.
Recovery of Cryopreserved Viruses

page 17 www.atcc.org Email [email protected]

 Preservation
1. In advance, grow the recommended production host in a prepared culture vessel that contains growth
medium equilibrated for both temperature and pH.
2. Remove the vial of frozen virus from the liquid nitrogen freezer and thaw by gentle agitation in a 37°C
water bath.
3. Thaw the strain rapidly until all ice crystals have melted (approximately 2 minutes).
4. Remove the vial from the water bath and decontaminate it by dipping in or spraying with 70% ethanol.
Follow strict aseptic conditions in a biological safety cabinet for all further manipulations.
5. Unscrew the top of the vial and inoculate the propagation host with the recommended infection
conditions as described on the supplied product sheet.
6. Examine the cultures after an appropriate length of time.

Lyophilization
Overview
Freeze-drying is a process where water and other solvents are removed from a frozen product via
sublimation¹⁵. Sublimation occurs when a frozen liquid goes directly to a gaseous state without entering a
liquid phase. The freeze-drying process results in a stable, readily rehydrated product. This process consists
of three steps: pre-freezing the product to form a frozen structure, primary drying to remove most water,
and secondary drying to remove bound water.
During the initial freezing process, ice crystals begin to form and the concentration of solutes in the
suspension increases. The method used during freezing can greatly affect the ability to freeze-dry the
material. Slow cooling rates are recommended as this will result in the formation of vertical ice crystal
structures and allow for more efficient water sublimation from the frozen product.
Freeze-dried products are hygroscopic and must be protected from moisture during storage. Additionally,
these products are sensitive to other factors including oxygen and temperature, which can significantly
decrease the shelf life. It is important to store freeze-dried material in a manner that protects the product
from exposure to moisture and oxygen and at refrigerated temperatures (4°C).
Generally, the lyophilization of viruses is not currently used by ATCC. This is because the methods for
lyophilization vary depending on the type of virus, and some viruses cannot be successfully preserved by
freeze-drying due to loss of viability. Strongly cell-associated viruses, including certain members of the
herpes virus family, such as varicella-zoster, lose viability outside the host. Therefore, these viruses cannot
be preserved by this method. Though ATCC does not currently freeze-dry any virus preparations, it was
done fairly extensively in the past. The methods of lyophilization that were previously used by ATCC are
described below. For additional information, contact ATCC technical services.
Equipment
A. Lyophilization Vials
For the storage of lyophilized viruses, ATCC uses sterile funnel-tipped glass ampoules (Wheaton)
and glass serum vials. Generally, during the lyophilization process, material is freeze-dried in a
glass ampoule, disinfected, and sealed.
B. Lyophilization Apparatuses
For the lyophilization of viruses, ATCC previously employed a commercial freeze-dryer. In this
freeze-drying procedure, samples are mixed with a suitable preservative, dispensed into the
appropriate ampoule, and allowed to slowly freeze into a solid mass. The preservative used for
lyophilization can vary between viral agents; several examples are listed below in Table 4. Once

Phone 800.638.6597 www.atcc.org page 18

Preservation
frozen, samples are lyophilized within a freeze-drying system (Virtis Genesis®, Millrock® Max 85,
and LD 85).
During the primary drying phase, water is removed from the frozen product via sublimation. This is
accomplished through the use of a vacuum pump, which allows water molecules to migrate from
the frozen product and condense on a moisture trap called a condenser. For this to be possible
the temperature of the condenser must be colder than the product temperature; the difference
in these temperatures will affect the rate of sublimation. When primary drying is complete, all
residual moisture is removed by directly heating the product. During this secondary drying phase,
water must be desorbed to a residual moisture content of 1% or less. This process requires a low
pressure, low condenser temperature system. Once dried, the ampoules are properly sealed and
stored at refrigerated temperatures (4˚C).
Table 4: Examples of Freeze-Dried Preparations

ATCC® No. Product Name Preparation

VR-343™ Japanese encephalitis virus Infected primary hamster kidney cells + 50% calf serum
Infected mouse brain (10% suspension in normal saline) diluted
VR-90™ Colorado tick fever virus
1:1 in rabbit serum
VR-897™ Influenza A virus Infected allantoic fluid + 10% sucrose

Storage and Viability of Lyophilized Strains

To maximize the recovery of viable cells, viral cultures must be in optimum condition before the lyophilization
process¹⁶. Viruses should be propagated under the recommended conditions for infection as indicated on
the product sheet.
Because lyophilized products are hygroscopic, they must be stored under moisture-free conditions.
Additionally, other factors such as oxygen content and temperature can affect the shelf-life of freeze-dried
strains. Oxygen can chemically react with the product, negatively affecting culture viability. This reactivity
is directly proportional to storage temperature. Therefore, lyophilized products should be stored long-term
in liquid nitrogen.
Lyophilization Procedure
1. Grow the virus according to usual procedures
2. For freeze-drying viral suspensions, glucose, skim milk, or
Sucrose-Phosphate-Glutamate-Albumin (SPGA) should be
added before dispensing. The lyophilization of some viruses
may require specific preservation preparations; examples are
listed in Table 4.
3. In a biological safety cabinet, dispense the suspension into
either sterile funnel-tipped ampoules or serum vials. Plug the
ampoules loosely with slotted silicon rubber stoppers, and
place the ampoules in a freeze-dryer tray. Set an acrylic plate
on top of the stoppers.
4. Freeze-dry the material in a commercial freeze-dryer. Hold the
material at -30°C for 18-48 hours, depending on the additive. Then raise the shelf temperature to 10°C
per hour until the product temperature is 25°C.
5. When the cycles are complete, backfill the system with sterile nitrogen and press the caps into place.
Disinfect the outside of the ampoules and return them to the biological safety cabinet.

page 19 www.atcc.org Email [email protected]

 Preservation
6. Seal the vials. Funnel-tipped ampoules will need to be sealed by an oxygen-gas torch.
Recovery of Lyophilized Cells
1. To rehydrate freeze-dried strains, add sterile double-distilled water.
2. Mix well, dilute with culture medium, and add the virus to the propagation host cell culture.
3. Incubate strains under the recommended temperature and atmospheric conditions. Optimal conditions
are listed for each strain in the ATCC Catalogue of Animal Viruses & Antisera.

Preservation of Specific Strains

All viral strains can be cryopreserved and maintained in liquid nitrogen vapor, whereas only some strains
can by lyophilized. In preparation for cryopreservation or lyophilization, viral strains should be grown under
optimal conditions. This can include growth in chicken eggs or within tissue culture. Below, we provide
information on the preservation of common viral strains.
Adenoviruses
The less labile virus suspensions, such as human adenovirus, are
harvested in their culture media then dispensed into ampoules for
freezing.
Herpesviruses
Certain members of the herpes family, such as cytomegalovirus
or varicella-zoster, lose viability outside the host. Therefore, keep
infected cells intact prior to preservation.
Viruses grown in Chicken Embryos
Viruses harvested from chicken eggs as allantoic fluid or yolk sac Image of Adenovirus courtesy of Dr. G. William
preparations can be frozen or lyophilized. The high-protein content Gary, Jr., CDC
of the egg serves as a cryoprotectant, and other additives may not
be necessary.
Viruses grown in vivo
Viruses grown in vivo and harvested in organ suspensions are preserved by freezing. Add sterile 50%
glycerol or 10-50% serum as a cryoprotectant.

Special Hazards
Care must be taken during the cryopreservation or lyophilization of animal viruses. Problems such as
contamination, breakage of glass ampoules during handling and storage, dispersal of freeze-dried virus
when opening glass ampoules, and the handling of liquid nitrogen must all be considered. To prevent
contamination and the dispersal of viruses, aseptic technique must be followed. This can include the
decontamination of all equipment and vials as well as performing all preparations in a biological safety
cabinet. Additionally, protective clothing should be worn during preparation to prevent contamination as
well as to guard against harm due to contact with liquid nitrogen.

Phone 800.638.6597 www.atcc.org page 20

Biosafety and Disposal
Biosafety and Disposal

Biosafety
The need for precautions when experimenting with viral cultures depends upon the source and nature
of the biological material, the experimental procedure, and the laboratory/containment conditions. Since
every situation is different, the risks need to be identified for each individual strain and the appropriate
precautions need to be taken before any work begins.
More information on risk assessment and precautions can be found in the Center for Disease Control
(CDC) publication Biosafety in Microbiological and Biomedical Laboratories¹⁷. The text of this publication is
available in its entirety online at www.cdc.gov.
A biosafety level (BSL) is assigned to each viral strain for the purposes of packaging for safe shipment. ATCC
follows federal biosafety guidelines and takes several factors into consideration when assessing a potential
hazard, and in some cases the ATCC assigned biosafety level is more restrictive. Generally, ATCC only ships
and stores viruses with a biosafety level assignment of 1, 2, or 3.
Biosafety Level 1
• Work involving well-characterized viral strains not known to consistently cause disease in
immunocompetent adult humans.
• Work can be conducted on the bench top using aseptic technique, no special containment equipment
or facility is required.
Biosafety Level 2
• Work involving viral strains that pose a moderate hazard to health adult humans.
• Work should be conducted in designated biological safety cabinets within laboratories with restricted
access.
Biosafety Level 3
• Work involving indigenous or exotic agents that may cause serious or potentially lethal disease via
inhalation.
• Work should be conducted in biological safety cabinets localized inside a specialized BSL-3 containment
facility within laboratories with restricted access.
As the recipient of an ATCC virus, take into account not only the nature of the material but also the
manipulations employed during its handling when assessing the potential laboratory risk. Keep in mind
that there will be situations where the intended use of an agent may require more stringent precautions
than associated with the assigned biosafety level¹⁷.

Disposal of Infectious Materials

All viral cultures, stocks, and potentially infectious materials need to be properly decontaminated prior to
disposal. The written method for proper decontamination should be available in the laboratory and BSL
facility. Several methods of sterilization include use of an autoclave, chemical disinfection, incineration,
or any other validated decontamination method. More information on the disposal of viral cultures can
be found in the Center for Disease Control (CDC) publication Biosafety in Microbiological and Biomedical
Laboratories¹⁷.

page 21 www.atcc.org Email [email protected]

 Viral Authentication and Viability Testing
Viral Authentication and Viability Testing
When preparing a viral strain for distribution, ATCC performs numerous quality control (QC) assays to
guarantee that the product is of the highest standard before it reaches the consumer. All viral strains grown
in-house undergo viability testing as well as genotypic examinations to ensure that the strain identification
is accurate and the viral agent is sustainable. Described below are several tests used by ATCC for the
authentication and viability testing of animal viruses.

Viability Testing
Cytopathic effects (CPE)
For tissue-culture adapted viruses, viability is primarily monitored by
NOTE 6:
observing host cell appearance. During the synthesis of viral components, During early viral infection, cells
the host cell undergoes morphological and biochemical changes. These may become rounded or appear
deviations often result in degenerative changes known as cytopathic more refractive. More severe
CPE include focal degeneration,
effect. The degree of visible cell damage varies between viral species and vacuolization, cellular fusion, or
host cell lines. Some viruses cause little to no CPE in host cells, while others host cell death.
can destroy the host cell population. Characteristic CPE is best observed by
analyzing cultures daily¹⁸. (See NOTE 6)

Propagation of Human herpes virus 1 (ATCC® No. VR-260™) in Vero cells (ATCC® No. CCL-
81™). The left panel depicts uninfected CCL-81™ cells. The right panel depicts infected CCL-
81™ cells exhibiting CPE.

Hemagglutination
Many viruses can attach to molecules present on the surface of Direct Hemagglutination
red blood cells. At certain concentrations, a viral suspension may Positive Reation:
cause red blood cells to clump together. This natural phenomenon,
known as hemagglutination, prevents red blood cells from settling
out of suspension and has been adapted for use in viability testing Hemagglutinating virus Red blood cells Agglutination

and CEID viral titering. In a hemagglutination assay, chicken red Negative Reation:

blood cell suspensions are incubated with a serially diluted virus

and monitored for the formation of a red blood cell lattice. The end-
Non-hemagglutinating
point is taken to be the highest dilution of the virus suspension virus
Red blood cells No agglutination

that produces a positive result.

Image of Hemagglutination assay courtesy of Dr.
F.T. Forrester., CDC

Phone 800.638.6597 www.atcc.org page 22

Viral Authentication and Viability Testing
Hemadsorption Assay
The phenomenon of hemadsorption is dependent on the attachment of red blood cells to the surface of
cell monolayers infected with enveloped, hemagglutinin-producing viruses. This natural process can be
adapted as a general procedure to determine viral potency. In a hemadsorption assay, a red blood cell
suspension is incubated with an infected cell culture. If the cell monolayer is infected with a hemagglutinin-
producing virus, hemagglutinin is inserted into the cell plasma membrane during viral reproduction in
preparation for viral maturation. It is at these modified areas of the cell surface that red blood cells will
specifically bind. Thus, hemadsorption is indicative of the presence of viruses that produce hemagglutinin,
such as influenza, measles, mumps, and parainfluenza.
Viral Infectivity
Viral infectivity is often measured by calculating titer. Depending on the required host for viral propagation,
infectivity can be analyzed using a plaque assay or by determining the infectious dose in tissue culture
or embryonated chicken eggs. The basis of these assays is to measure the ability of an infectious viral
suspension to produce a pathological change in the host environment. For additional information on
plaque assays or calculating infectious dose, refer to the chapter entitled “Viral Replication and Propagation”.

Viral Authentication
Sequencing
The ATCC Virology collection utilizes sequencing to authenticate
our holdings as they are accessioned or come up for replenishment.
ATCC sequences approximately ≥500 bp of the viral genome that is
characteristic of the species or virus type.
Enzyme Linked Immunosorbant Assay
All viruses have at least one unique surface antigen. Through an
enzyme-linked immunosorbant assay (ELISA), these antigens can
be used as a biological marker to authenticate a viral species.
There are two forms of this assay, the direct and indirect ELISA.
Both assays employ enzyme-conjugated monoclonal detection antibodies that tightly bind a specific viral
antigen. With a direct ELISA, one is testing for the presence of the virus, while an indirect ELISA assay detects
specific viral antibody rather than the virus itself. The presence of a specific virus is analyzed by assessing
the conjugated enzyme activity via incubation with a substrate that is converted into a measurable colored
product. When using an ELISA for authentication purposes, a colorimetric change indicates the viral sample
was correctly identified.

page 23 www.atcc.org Email [email protected]

 Viral Applications
Viral Applications

Cell Transformation
Cancerous cells emerge due to discrete changes in the cellular genome. These genomic deviations can
arise due to viral transformation. During the infection of non-permissive cells, viral genetic material can
become covalently integrated into the host genome. If viral integration induces the aberrant expression of
a proto-oncogene, cell growth can become unrestricted, resulting in an immortal cell state.
This natural process has been adapted by cell biologists for use in the immortalization of mammalian cells
in tissue culture. Immortalized cell lines offer the possibility of an inexhaustible supply of cells, allowing for
more consistent and reproducible research. Viral genes such as the simian virus 40 (SV40) T antigen have
been used as a simple, reliable agent for the immortalization of a variety of cell types¹⁹, ²⁰. SV40 is believed
to induce immortalization by suppressing the transcription of p53, a tumor suppressor protein responsible
for initiating apoptosis following cell damage.
In addition to their use in cell immortalization, viral strains can be used to introduce nucleic acids into cells.
This process, termed transduction, allows scientists to analyze the function of specific genes, to examine
the effects of gene silencing, or to introduce therapeutic genes.

Phage Therapy
Bacteriophages are viruses that infect bacterial cells, often resulting
in the lysis and subsequent death of the bacterial host. Since the
early 20th century, European scientists have taken advantage of this
natural process to treat bacterial infections in a process known as
phage therapy. Because the host range of a bacteriophage is very
narrow, often specific to one species, they are considered more
effective than antibiotic treatment and result in less harm to the
human microflora²². Though phage therapy has many benefits, it
was abandoned by many countries due to the antigenic properties
and unpredictable behavior of bacteriophages in addition to the
wide-spread production and use of antibiotics. However, with the recent emergence of antibiotic-resistant
bacteria, scientists are now forced to re-evaluate the beneficial properties of the application of phage
therapy²³.

Nanotechnology
Cancer treatments have commonly employed surgery, radiation, chemotherapy, and hormone therapy²⁴.
Though these treatments have helped millions of patients go into remission, they come at a cost. Most
cancer treatments attack both healthy and cancerous cells, often leaving patients nauseous, fatigued, and
immunocompromised. To combat these negative side effects, viral nanoparticles are being engineered and
analyzed as a potential form of drug delivery.
Viral nanoparticles are viruses whose genomic material has been removed and replaced with therapeutic
drugs. Because viruses have naturally evolved the ability to cross the host cell membrane, they are an ideal
candidate for drug packaging and targeted delivery. To minimize toxic side effects, infection, and induced

Phone 800.638.6597 www.atcc.org page 24

Viral Applications
immune response, human viruses are not used in the production of viral nanoparticles. Rather, these drug
delivery systems are engineered from plant, insect, and animal viruses²⁵. Plant viruses, such as the Cowpea
mosaic virus, are ideal candidates for nanotechnology as they are easy to produce in large quantities, can
self-assemble around a nanoparticle, and hold a substantial volume of cancer drugs²⁶.
One of the major benefits to using viral nanoparticles for drug delivery is that targeting molecules can be
easily attached to the viral surface, allowing for the directed binding to cancer cells. This specific binding
prevents the harm or death of surrounding healthy cells, thus reducing possible side effects. Though viral
nanoparticles have the potential to be a beneficial treatment, there are several complications associated
with their use as a drug delivery system including immune rejection and potential toxicity. Regardless, viral
nanoparticles have the capability to revolutionize the treatment of cancer, creating a safe and specific form
of drug delivery.

Recombinant Vectored Vaccines

Vaccines are the most effective prophylactic tool for the prevention of disease. Viral-based vaccines are
traditionally employed as live attenuated viruses or as chemically inactivated viruses. Though these types
of preparations have been shown to induce protective immunity in animal models, incomplete viral
attenuation or inactivation poses a serious risk to those who are vaccinated²⁷, ²⁸. Recombinant vectored
vaccines, however, offer a live-vaccine approach that does not employ the complete pathogen. Instead,
genetic material from the microbial target strain is inserted into the genome of harmless viral strains,
allowing for the safe expression of microbial antigens.
Newcastle disease virus (NDV), a negative-sense RNA avian virus, is a common template used for the
development of recombinant vectored vaccines. Not only does NDV grow to high titers in many cell
lines and eggs, it can elicit a strong immune response in vivo, is harmless to humans, and is commercially
available. Additionally, NDV replicates in the cytoplasm of infected cells, thus eliminating the problem of
genetic integration²⁹. To create a viral vaccine vector from NDV, genes encoding foreign target proteins are
inserted into the NDV genome through recombination. Upon vaccination with the live virus, the foreign
target protein is expressed within the host cell cytoplasm where it is then available for processing by the
cellular antigen-processing machinery for immune presentation. As a result, cellular immunity is activated
and neutralizing antibodies are generated³⁰-³².

page 25 www.atcc.org Email [email protected]

 Glossary
Glossary
Ambisense. A term applied to single-stranded RNA viral genomes. Part of the nucleotide sequence is
positive-sense and part is negative-sense.
Complex morphology. A virus that possesses a capsid that is neither truly helical nor icosahedral. This
morphology may have additional structures such as a protein tail or a complex outer wall.
Cytopathic effect (CPE). CPE refers to the degenerative changes in association with viral infection.
Effect. Degenerative changes in the product host as a result of viral infection.
Enveloped morphology. Viral envelopes are commonly derived from portions of the host cell membranes
that have incorporated viral glycoproteins. Envelopes surround the viral capsid and assist in viral entry of
host cells.
Helical morphology. Viral morphology composed of a single type of capsomer stacked around a central
axis to form a helical structure.
Hemagglutination. This term refers to the agglutination, or clumping, of red blood cells.
Icosahedral morphology. Viral structures built from repeated identical protein subunits to form a nearly
spherical structure with rotational symmetry.
Multiplicity of infection (MOI). The ratio of agents (e.g. viruses, bacteriophages, bacteria) to infection
targets (e.g. propagation host)
Negative sense. Negative-sense RNA (3’ to 5’) forms the complementary strand and must be converted to
positive-sense by an RNA polymerase prior to translation.
Non-permissive. Being or relating to a cell or environmental condition that does not support the replication
of a virus or bacteriophage.
Positive sense. Positive-sense RNA (5’ to 3’) signifies that a particular sequence can be directly translated
into protein.
Production host. The host strain used for the propagation of viruses.
Prolate morphology. Viral morphology composed of a cylinder with a cap at either end forming an
elongated icosahedron structure along a fivefold axis. This is a common arrangement of bacteriophage
heads.
Proto-oncogene. This term defines a normal gene that can become an oncogene due to mutations or
increased expression. These genes commonly code for proteins involved in the regulation of cell growth or
differentiation.
Sense. Sense is a concept used to compare the polarity of nucleic acids.
Transfection. This term refers to the process of deliberately introducing nucleic acids into cells.
Transformation. This term refers to the cellular alteration resulting from the uptake, integration, and
expression of exogenous genetic material taken up from the environment.

Phone 800.638.6597 www.atcc.org page 26

Appendix
Appendix
Propagation hosts and recommended basal media
ATCC® No. Product Description ATCC® No. Media
CCL-81.5™ Vero-SF-ACF ACS-4001 VeroPlus Serum-Free Medium
CCL-22™ MDBK (NBL-1) 30-2003 Eagle’s Minimum Essential Medium
CCL-34™ MDCK (NBL-2) 30-2003 Eagle’s Minimum Essential Medium
CRL-1590™ SL-29 30-2002 Dulbecco’s Modified Eagle’s Medium
CCL-10™ BHK-21 30-2003 Eagle’s Minimum Essential Medium
CCL-61™ CHO-K1 30-2004 F-12K Medium
CRL-1573™ 293 (HEK-293) 30-2003 Eagle’s Minimum Essential Medium
CCL-2™ HeLa 30-2003 Eagle’s Minimum Essential Medium
CCL-23™ Hep-2 30-2003 Eagle’s Minimum Essential Medium
CCL-171™ MRC-5 30-2003 Eagle’s Minimum Essential Medium
CCL-75™ WI-38 30-2003 Eagle’s Minimum Essential Medium
CRL-1721™ Sf9 30-2001 RPMI-1640 Medium
CRL-1651™ COS-7 30-2002 Dulbecco’s Modified Eagle’s Medium
CCL-81™ Vero 30-2003 Eagle’s Minimum Essential Medium
CRL-1586™ VERO C1008 [Vero 76, clone E6, Vero E6] 30-2003 Eagle’s Minimum Essential Medium
CRL-1587™ VERO 76 30-2002 Dulbecco’s Modified Eagle’s Medium
CCL-7.1™ LLC-MK2 Derivative 30-2003 Eagle’s Minimum Essential Medium
CL-160™ DBS-FRhL-2 30-2003 Eagle’s Minimum Essential Medium
CCL-33™ PK(15) 30-2003 Eagle’s Minimum Essential Medium

page 27 www.atcc.org Email [email protected]

 References
References
1. Rovozzo, G. & Burke, C. A Manual of Basic Virological Techniques (Prentice-Hall, 1973).
2. Leland, D. & Ginocchino, C. Role of Cell Culture for Virus Detection in the Age of Technology. Clin
Microbiol Rev 20, 49-78 (2007).
3. Cohen, J.I. Epstein-Barr virus infection. N Engl J Med 343, 481-92 (2000).
4. Gotoh, K. et al. Replication of Epstein-Barr virus primary infection in human tonsil tissue explants. PLoS
One 6, e25490.
5. Mahy, B. & Kangro, H. Virology Methods manual (Academic Press, 1996).
6. Reed, L. & Muench, H. A simple method of estimating fifty percent endpoints. American Journal of
Hygiene 27, 493-497 (1938).
7. McLimans, W. (eds. Rothblat, G. & Cristofalo, V.) (Academic Press, New York, 1972).
8. Shipman, C., Jr. Evaluation of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) as a tissue
culture buffer. Proc Soc Exp Biol Med 130, 305-10 (1969).
9. Giandomenico, A.R., Cerniglia, G.E., Biaglow, J.E., Stevens, C.W. & Koch, C.J. The importance of sodium
pyruvate in assessing damage produced by hydrogen peroxide. Free Radic Biol Med 23, 426-34 (1997).
10. Jacoby, W. & Pasten, I. (Academic Press, New York, 1979).
11. Mazur, P. The role of intracellular freezing in the death of cells cooled at supraoptimal rates. Cryobiology
14, 251-72 (1977).
12. Mazur, P. Cryobiology: the freezing of biological systems. Science 168, 939-49 (1970).
13. Fahy, G.M. The relevance of cryoprotectant "toxicity" to cryobiology. Cryobiology 23, 1-13 (1986).
14. Meryman, H.T. Cryoprotective agents. Cryobiology 8, 173-83 (1971).
15. Rowe, T.W. Optimization in freeze-drying. Dev Biol Stand 36, 79-97 (1976).
16. Heckly, R. Principles of preserving bacteria by freeze-drying. Dev Ind Microbiol 26, 379-395 (1985).
17. United States Department of Health and Human Serves, C.f.D.C., and National Institutes of Health.
Biosafety in Microbiological and Biomedical Laboratories (U.S. Government Printing Office, HHS
Publication No. (CDC) 21-1112, Washington DC, 2009).
18. Enders, J.F. Cytopathology of virus infections: particular reference to tissue culture studies. Annu Rev
Microbiol 8, 473-502 (1954).
19. Jha, K.K., Banga, S., Palejwala, V. & Ozer, H.L. SV40-Mediated immortalization. Exp Cell Res 245, 1-7 (1998).
20. Kirchhoff, C. et al. Immortalization by large T-antigen of the adult epididymal duct epithelium. Mol Cell
Endocrinol 216, 83-94 (2004).
21. Mancheno-Corvo, P. & Martin-Duque, P. Viral gene therapy. Clin Transl Oncol 8, 858-67 (2006).
22. Miedzybrodzki, R. et al. Clinical aspects of phage therapy. Adv Virus Res 83, 73-121.
23. Kropinski, A.M. Phage Therapy - Everything Old is New Again. Can J Infect Dis Med Microbiol 17, 297-306
(2006).
24. Institute, N.C. (2011).
25. Singh, P., Destito, G., Schneemann, A. & Manchester, M. Canine parvovirus-like particles, a novel
nanomaterial for tumor targeting. J Nanobiotechnology 4, 2 (2006).
26. Franzen, S. & Lommel, S.A. Targeting cancer with 'smart bombs': equipping plant virus nanoparticles for
a 'seek and destroy' mission. Nanomedicine (Lond) 4, 575-88 (2009).
27. Brown, F. Review of accidents caused by incomplete inactivation of viruses. Dev Biol Stand 81, 103-7 (1993).

Phone 800.638.6597 www.atcc.org page 28

References
28. Nathanson, N. & Langmuir, A.D. The Cutter Incident. Poliomyelitis Following Formaldehyde- Inactivated
Poliovirus Vaccination in the United States during the Spring of 1955. Ii. Relationship of Poliomyelitis to
Cutter Vaccine. Am J Hyg 78, 29-60 (1963).
29. Huang, Z., Elankumaran, S., Panda, A. & Samal, S.K. Recombinant Newcastle disease virus as a vaccine
vector. Poult Sci 82, 899-906 (2003).
30. Huang, J.L. et al. High-level expression of recombinant dengue viral NS-1 protein and its potential use
as a diagnostic antigen. J Med Virol 65, 553-60 (2001).
31. Krishnamurthy, S., Huang, Z. & Samal, S.K. Recovery of a virulent strain of newcastle disease virus from
cloned cDNA: expression of a foreign gene results in growth retardation and attenuation. Virology 278,
168-82 (2000).
32. Nakaya, T. et al. Recombinant Newcastle disease virus as a vaccine vector. J Virol 75, 11868-73 (2001).

page 29 www.atcc.org Email [email protected]

 

Phone 800.638.6597 www.atcc.org page 30

ATCC Reagents for Virus Expansion
ATCC Reagents for Virus Expansion
ATCC Cell Lines for virus expansion
ATCC® No. Product Name Organism Tissue Source
CCL-22™ MDBK Bovine Kidney
CCL-34™ MDCK (NBL-2) Canine Kidney
CRL-1590™ SL-29 Chicken Embryo
CCL-10™ BHK-21 Hamster Kidney
CCL-61™ CHO-K1 Hamster Ovary
CRL-1573™ 293 (HEK-293) Human Kidney
CRL-1573.3™ HEK-293.2sus Human Kidney
CCL-2™ HeLa Human Cervix
CCL-23™ Hep-2 Human Cervix
CCL-171™ MRC-5 Human Lung
CCL-75™ WI-38 Human Lung
CRL-1721™ Sf9 Insect Ovary
CRL-1651™ COS-7 Monkey Kidney
CCL-81.5™ Vero-SF-ACF Monkey Kidney
CCL-81™ Vero Monkey Kidney
CRL-1586™ VERO C1008 [Vero 76, clone E6, Vero E6] Monkey Kidney
CRL-1587™ VERO 76 Monkey Kidney
CCL-7.1™ LLC-MK2 Derivative Monkey Kidney
CL-160™ DBS-FRhL-2 Monkey Lung
CCL-33™ PK(15) Pig Kidney

ATCC Media product list

ATCC® No. Product Name Volume
30-2002 Dulbecco's Modified Eagle's Medium (DMEM) 500 mL
ACS-4001 VeroPlus SFM (serum-free media) 500 mL
ACS-4002 HEKPlus SFM (serum-free medium) 500 mL
30-2006 DMEM:F12 Medium (1:1 Ratio) 500 mL
30-2003 Eagle's Minimum Essential Medium (EMEM) 500 mL
30-2004 F12K Medium 500 mL
30-2005 Iscove's Modified Dulbecco's Medium (IMDM) 500 mL
30-2008 Leibovitz's L-15 Medium 500 mL
30-2007 McCoy's 5A Medium, Modified 500 mL
30-2001 RPMI-1640 Medium 500 mL

page 31 www.atcc.org Email [email protected]

 ATCC Reagents for Virus Expansion

Animal Sera product list

ATCC® No. Product Name Volume
30-2020 Fetal Bovine Serum 500 mL
30-2030 Calf Bovine Serum 500 mL
30-2040 Horse Serum 500 mL

Cell Culture Supplements

ATCC® No. Product Name
AMINO ACID SOLUTIONS
30-2214 L-Glutamine Solution, 200 mM
30-2116 MEM Non-Essential Amino Acid Solution, 100x
SUBCULTURE REAGENTS
30-2101 Trypsin EDTA Solution
30-2103 Non-Enzymatic Cell Dissociation Solution
30-2104 Soybean Trypsin Inhibitor
BUFFERS, STAINS & WATER
30-2200 Dulbecco's Phosphate Buffered Saline (DPBS)
30-2404 Erythrosin B Stain Solution, 40 mL
30-2205 Water, Cell Culture Grade
CRYOPRESERVATION REAGENTS AND TOOLS
4-X Dimethylsulfoxide (DMSO)
30-2600 Serum-Free Cell Freezing Medium
ACS-6000 CoolCell LX Alcohol-free Freezing Container

Cell Proliferation Assays and Mycoplasma Detection

ATCC® No. Product Name
30-1010K ATCC MTT Cell Proliferation Assay
30-1011K XTT Cell Proliferation Assay Kit
30-1012K Universal Mycoplasma Detection Kit

Phone 800.638.6597 www.atcc.org page 32

10801 University Blvd.
Manassas, VA 20110

Tel 800.638.6597
703.365.2700

Fax 703.365.2750

Email [email protected]

Web www.atcc.org

Or contact your local distributor at

www.atcc.org/distributor

V-0716-04

© 2016 American Type Culture Collection.

The ATCC trademark and trade name, and any
other trademarks listed in this publication are
trademarks owned by the American Type Culture
Collection unless indicated otherwise.

CoolCell® (BioCision, LLC); VirTis® (SP Industries,

Inc.); and Millrock Technology® (Millrock
Technology, Inc.)
Top front image of Respiratory Synchytial Virus
courtesy of Dr. Craig Lyerla, CDC. Hepatitis image courtesy of Dr. Erskine Palmer, CDC